ATOLL lessons favors enoxaparin at an end UFH during acme Percutaneous Coronary Intervention
Posted in Drug Trial on August 30th, 2010– Composite Pure Endpoint: Jeopardy Reduction of 17% (Non-Statistically Substantial ) in Liquidation, Involvement of Myocardial Infraction, Methodology Collapse or Noteworthy Bleeding
– Gas main Alternate Composite Efficacy Endpoint: 40% Reduction of Expiry, Recurring Stabbing Coronary Syndrome or Re-Intervention
The cosmopolitan ATOLL enquiry sponsored by way of the Help Publique – Hopitaux de Paris showed that enoxaparin reduced Read the rest of this entry »
